Debiopharm and Oncodesign Partner to Advance Radioimmunotherapy Preclinical Studies

• Debiopharm has signed a licensing agreement with Oncodesign Services for the use of its AbYlink bioconjugation technology in preclinical services.

• The technology will support non-invasive diagnostic studies, particularly in molecular radiotherapy targeting HER2+ tumours.

Debiopharm Research & Manufacturing S.A. and Oncodesign Services have entered into a licensing agreement that grants the contract research organisation the rights to use Debiopharm’s proprietary AbYlink technology for preclinical applications. The collaboration will focus on advancing the development of novel cancer treatment approaches in molecular radiotherapy, especially radioimmunotherapy.

The agreement enables Oncodesign Services to use the regio-selective bioconjugation platform to produce antibody chelator conjugates for use in non-invasive imaging studies. These studies are aimed at evaluating the predictive effectiveness of new therapeutics in animal models, with a specific focus on HER2-positive tumours. Results from these joint efforts are expected to be presented at the AACR Annual Meeting in 2025.

AbYlink allows for rapid and covalent conjugation of antibodies with imaging agents in a single step. The technology is intended to support pharmaceutical and biotech companies working on antibody-drug conjugates (ADCs) and targeted radiotherapies. As stated by Frédéric Lévy, Chief Scientific Officer at Debiopharm, “Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications.”

Aidan Synnott, CEO of Oncodesign Services, added that the platform strengthens their service offering by providing reproducible bioconjugated antibody batches, supporting precision in targeted therapies.